Brian Cheng
Stock Analyst at JP Morgan
(3.33)
# 993
Out of 5,241 analysts
85
Total ratings
49.28%
Success rate
3.56%
Average return
Main Sectors:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARA Protara Therapeutics | Maintains: Overweight | $27 → $26 | $5.10 | +409.80% | 2 | May 14, 2026 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $30 → $29 | $9.49 | +205.58% | 3 | May 13, 2026 | |
| CGON CG Oncology | Maintains: Overweight | $91 → $96 | $66.93 | +43.43% | 4 | May 11, 2026 | |
| GLUE Monte Rosa Therapeutics | Maintains: Overweight | $30 → $31 | $18.15 | +70.80% | 1 | May 11, 2026 | |
| XNCR Xencor | Maintains: Neutral | $13 → $14 | $11.22 | +24.78% | 7 | May 11, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Overweight | $88 | $76.67 | +14.78% | 1 | May 1, 2026 | |
| ALLO Allogene Therapeutics | Upgrades: Neutral | n/a | $2.00 | - | 6 | Apr 16, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $95 → $106 | $102.18 | +3.74% | 7 | Mar 19, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Overweight | $29 | $13.25 | +118.87% | 1 | Mar 2, 2026 | |
| TGTX TG Therapeutics | Maintains: Overweight | $49 → $46 | $39.50 | +16.46% | 1 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $122 | $145.66 | -16.24% | 2 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $125 | $82.21 | +52.05% | 1 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.10 | - | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $12 → $5 | $13.67 | -63.42% | 5 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $23 | $23.93 | -3.89% | 3 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.15 | - | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $5.13 | - | 1 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $33 | $27.49 | +20.04% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $20 | $29.29 | -31.72% | 7 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $48.41 | +44.60% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.42 | - | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $20.88 | +5.36% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $19.50 | - | 1 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.62 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.31 | +358.02% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $850 → $700 | $4.27 | +16,293.44% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.25 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $320 → $96 | $7.68 | +1,150.00% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.01 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.34 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $7.47 | +1,037.88% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $9.02 | +132.82% | 1 | Aug 3, 2021 |
Protara Therapeutics
May 14, 2026
Maintains: Overweight
Price Target: $27 → $26
Current: $5.10
Upside: +409.80%
Kyverna Therapeutics
May 13, 2026
Maintains: Overweight
Price Target: $30 → $29
Current: $9.49
Upside: +205.58%
CG Oncology
May 11, 2026
Maintains: Overweight
Price Target: $91 → $96
Current: $66.93
Upside: +43.43%
Monte Rosa Therapeutics
May 11, 2026
Maintains: Overweight
Price Target: $30 → $31
Current: $18.15
Upside: +70.80%
Xencor
May 11, 2026
Maintains: Neutral
Price Target: $13 → $14
Current: $11.22
Upside: +24.78%
Arrowhead Pharmaceuticals
May 1, 2026
Initiates: Overweight
Price Target: $88
Current: $76.67
Upside: +14.78%
Allogene Therapeutics
Apr 16, 2026
Upgrades: Neutral
Price Target: n/a
Current: $2.00
Upside: -
Protagonist Therapeutics
Mar 19, 2026
Maintains: Overweight
Price Target: $95 → $106
Current: $102.18
Upside: +3.74%
Eikon Therapeutics
Mar 2, 2026
Initiates: Overweight
Price Target: $29
Current: $13.25
Upside: +118.87%
TG Therapeutics
Feb 2, 2026
Maintains: Overweight
Price Target: $49 → $46
Current: $39.50
Upside: +16.46%
Feb 2, 2026
Maintains: Overweight
Price Target: $92 → $122
Current: $145.66
Upside: -16.24%
Dec 10, 2025
Maintains: Overweight
Price Target: $70 → $125
Current: $82.21
Upside: +52.05%
Nov 20, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.10
Upside: -
Nov 7, 2025
Downgrades: Underweight
Price Target: $12 → $5
Current: $13.67
Upside: -63.42%
Oct 16, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $23.93
Upside: -3.89%
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.15
Upside: -
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.13
Upside: -
Sep 30, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $27.49
Upside: +20.04%
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $29.29
Upside: -31.72%
Sep 18, 2025
Initiates: Overweight
Price Target: $70
Current: $48.41
Upside: +44.60%
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $4.42
Upside: -
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $20.88
Upside: +5.36%
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $19.50
Upside: -
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $2.62
Upside: -
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.31
Upside: +358.02%
Sep 25, 2023
Maintains: Overweight
Price Target: $850 → $700
Current: $4.27
Upside: +16,293.44%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.25
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $320 → $96
Current: $7.68
Upside: +1,150.00%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $1.01
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.34
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $7.47
Upside: +1,037.88%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $9.02
Upside: +132.82%